Search

Early detection of skin cancer significantly improves the five-year survival rate for patients. However, due to the subtle nature of early malignant tumors in the skin, their symptoms are not apparent, and specialized doctors need to perform multiple biopsies and extract lesion tissues to diagnose the type of lesion. Traditional artificial intelligence methods have low accuracy in identifying skin lesion images primarily because they are difficult to simultaneously focus on spatial details and shallow semantic features. To effectively represent spatial positions and shallow feature information, and avoid the model being overly concerned with detailed information, which can lead to misclassification of easily distinguishable images, a progressive aggregation attention network based on ConvNeXt is proposed. This method utilizes a hierarchical ConvNeXt encoder to extract deep and shallow features of lesion regions layer by layer. By employing parallel spatial attention, it effectively integrates spatial position information with deep or shallow semantic features, aggregating multi-scale contextual information. Meanwhile, a progressive feature aggregation module is designed to effectively integrate deep and shallow features and aggregate them by dynamically adjusting weights, closely aligning with the process of rough observation and meticulous examination in skin image classification by specialized doctors. Experimental tests on the ISIC2018 and ISIC2019 datasets show that the accuracy, precision, recall, and F1-Score of this method are 95.27%, 93.76%, 92.83%, and 93.18%, respectively, for ISIC2018, and 92.63%, 91.06%, 87.05%, and 88.81%, respectively, for ISIC2019. Compared to ConvNeXt, the accuracy is improved by 2.13 and 3.29 percentage points respectively, demonstrating its ability to effectively extract detailed and rough features, providing new evidence for the diagnosis of skin image through dermatoscopy. [ABSTRACT FROM AUTHOR]

Background Community health service center is the main gatekeeper for breast cancer screening, while its efficacy of screening is difficult to guarantee for the re-striction of screening process by various factors. Objective To analyze the focus issue of breast cancer screening program in the real world and explore corresponding solutions. Methods A mixed-methods convergent design was used to collect quantitative and quali-tative data. In the quantitative study, typical sampling method was used to select one community health service center in each of the four districts of Tianjin as the investigation institution from April 2021 to November 2022, accidental sampling method was used to select age-eligible women within 3 km of the four institutions as resident survey respondents, so as to explore the issues existing in the on-site operation of breast cancer screening. In the qualitative study, 9 residents, 12 physicians participating in the screening and 4 leaders were selected through purposive sampling from June to November 2022 for semi-structured in-terviews. The grounded theory was used to analyze the interview content, and the grounded theory framework of the focus issues of breast cancer screening was plotted. Combined with literature and typical investigation data, a mixed methods study was conducted to determine the focus issues of breast cancer screening. Results The quantitative study showed that in the advocacy work, the promotion method is traditional, the awareness rate and participation rate of residents was 46.3% (143/309) and 32.4% (100/309) , respectively; in the screening work, the institutions invested different human and material resources, and the average waiting time of screening residents accounted for 62.2% (40.5/65.1) of the total time; in the follow-up and referral work, the invested human and material resources were little, the mammography referral compliance of residents was 29.9% (59/197) . The qualitative study showed that a total of 38 comprehensive open codes were formed in the interview and converged into 10 axial codes and 3 core codes, including advocacy organization, screening organization, follow-up and referral. The mixed methods study showed that 3 focus issues were identified in final, including how to improve residents' participation rate, how to ensure adequate human and material resources in screening institutions, and how to improve residents' mammography referral compliance. Conclusion The efficacy of breast cancer screening is influenced by advocacy organization, screening organization, follow-up and referral. It is necessary to rationally allocate resources to ensure adequate human and material resources for screening institutions; innovate promotion methods, expand coverage of promotion and improve residents' health literacy, participation rates and mammography referral compliance, to ensure the substantial progress of breast cancer screening and provide reference for opti-mizing the efficacy of breast cancer screening.

Background Due to many barriers, it is difficult for primary medical institutions to ensure substantial achievements in breast cancer screening. So it is particularly important to establish a system for scientifically and effectively assessing the capacities of primary care institutions in conducting breast cancer screening. Objective To construct a system for assessing the capacities of primary care institutions for conducting breast cancer screening. Methods From September to October 2022, through literature review and group discussion, we developed an item pool of the initial version of Breast Cancer Screening Capacity Assessment System for Primary Care Institutions (BCSCASPCI) . Then we conducted an online Delphi survey between November and December 2022 using a self-developed questionnaire with a purposive sample of 21 experts for understanding their views regarding the initial version of BCSCASPCI, and the response coefficient, authority coefficient, and the Kendall's W of the survey were calculated. Finally, based on the results of the survey and a group discussion, the final version of the BCSCASPCI was determined. The Analytic Hierarchy Process was used to determine the weight coefficients of its indicators and to examine the logical consistency of indicators. Results All the experts returned effective questionnaires, achieving a response rate of 100.0%, and the authority coefficient was 0.812, and the Kendall's W was 0.209 (P

Small cell lung cancer (SCLC) is a type of lung cancer with high malignant degree, rapid transformation, rapid invasion and metastasis, which is prone to early metastasis and poor prognosis. Bone metastases of SCLC occur in three stages: cancer cells proliferate at the primary site, break through local tissues, enter the blood circulation to form circulating tumor cells (CTCs), reach bone tissue through blood circulation, and take root and germinate to form new tumor sites with the support of the bone microenvironment. However, traditional imaging and pathology examinations have disadvantages such as low sensitivity, high cost and difficulty in implementation. Exploratory studies based on blood marker detection as screening and efficacy evaluation of SCLC bone metastases have been reported in recent years. By reviewing the molecular biological mechanism of SCLC bone metastasis formation, this paper found that conventional diagnostic methods such as imaging and pathological biopsy were inadequate in SCLC bone metastasis. The changes in hyaluronic acid, protein biomarkers, non-coding RNA, and biomarkers in liquid biopsy were earlier than the changes in imaging, which had the advantages of simple operation and good repeatability. It provides a new idea and method for the early diagnosis of SCLC bone metastasis, which is worthy of clinical application. [ABSTRACT FROM AUTHOR]

The development and change patterns as well as the disease course management of multiple ground-glass nodules (GGNs) in the lungs are currently hotspots and difficulties in clinical lung cancer research. Understanding the latest advancements in the natural history of multiple GGNs is crucial for grasping the disease variation patterns and formulating management strategies. Meanwhile, utilizing advanced methods such as intelligent follow-up management platforms makes the long-term standardized management of GGNs possible. Therefore, this article provides an overview of the latest research advancements on the natural history of multiple GGNs and new experience in GGNs management. [ABSTRACT FROM AUTHOR]

Background and objective The incidence rate of lung cancer in Xuanwei has been continuously increasing in recent years, and it also features high incidence across all age groups and high mortality rates among female lung cancer patients. Therefore, the search for more stable biomarkers for the diagnosis of Xuanwei lung cancer holds tremendous clinical application prospects. This study aims to explore the clinical application value of these four microRNAs (miRNAs) individually and in combination with traditional lung cancer tumor markers in the detection and diagnosis of Xuanwei lung cancer. Methods By detecting the expression levels of four miRNAs and five traditional lung cancer tumor markers in the serum of 45 Xuanwei lung cancer patients and healthy physical examination participants, the Logistic regression model was employed to comprehensively evaluate the sensitivity, specificity, diagnostic efficacy, and other relevant statistical indicators of the four miRNAs in the diagnosis of Xuanwei lung cancer. Results Among the individual miRNAs, miR-4646-5p and miR-3654 showed significant differences in expression levels between the Xuanwei lung cancer group and the control group (P<0.05). miR-3654 demonstrated the best diagnostic performance with a sensitivity of 86.7%, specificity of 82.2%, and an area under the curve of 0.847. Combining miR-3654 with miR-4646-5p and carcinoembryonic antigen (CEA) resulted in the highest diagnostic ef- ficacy for Xuanwei lung cancer, with a sensitivity of 73.3%, specificity of 93.3%, area under the curve of 0.901, and a positive predictive value of 91.7%. Conclusion Among the four miRNAs, serum miR-3654 exhibits the best diagnostic efficacy for Xuanwei lung cancer. Combined with miR-4646-5p and CEA, its diagnostic value for Xuanwei lung cancer can be effectively enhanced, making it a promising screening indicator for Xuanwei lung cancer. [ABSTRACT FROM AUTHOR]

Objective To analyze the risks and related influencing factors of early screening for lung cancer, and to study prognostic factors based on survival conditions, in order to ultimately provide baseline data for the prevention and treatment of lung cancer. Methods A cluster sampling method was used to select 40 to 75 year old registered residence residents in 10 districts and 6 counties of Zhengzhou City in 2020 as screening objects. Through voluntary participation and filling in evaluation questionnaires, high-risk groups of lung cancer were evaluated, and then three screening tests (tumor markers, low-dose spiral CT and lung function) were performed on high-risk groups. Finally, we will adopt an active and passive follow-up approach to collect information on diagnosed lung cancer patients. Statistically describe the screening data and describe the epidemiological results of different characteristic populations; Using multivariate logistic regression method for statistical analysis, compare the differences in various results of different factors. Results 50 128 cases of early screening for lung cancer in Zhengzhou City were evaluated in 2020, with a completion rate of 100.26%. The average age of the survey was (59.86 ± 17.67) years old, and the gender ratio was 0.81:1. The high-risk detection rate is 30.15%. Multivariate logistic regression analysis showed that males (smoking) (OR = 5.43, 95% CI: 5.20 ~ 5.67), individuals with a history of tobacco exposure (OR = 3.82, 95% CI: 3.67 ~ 3.98), first-degree relatives who had previously suffered from lung cancer (OR = 12.06, 95% CI: 11.02 ~ 13.20), and other populations were more susceptible to lung cancer (all P < 0.05). Conclusion Male (smoking), exposure to secondhand smoke, cancer in first-degree relatives, previous diagnosis of other tumors, symptoms of lung infection, "chest tightness, shortness of breath, and difficulty breathing in daily life", and "significant psychological trauma in the past 3 years" are independent risk factors for lung cancer, which should be given special attention and effective intervention measures should be taken. [ABSTRACT FROM AUTHOR]

Objective: To screen the key genes affecting the prognosis and treatment of gastric cancer (GC) patients and to analyze the value of the key gene microfibrillar-associated protein 2 (MFAP2) in suggesting the prognosis and the sensitivity of immunotherapy of GC patients. Methods: The expression profile data and clinical information of gastric cancer and paracancerous tissues were downloaded from the TCGA database. Genes significantly associated with the prognosis of gastric cancer were screened by weighted gene co-expression network analysis (WGCNA) and univariate Cox regression analysis. Multiple patient cohorts were used to assess the prognostic value of the key gene MFAP2 and analyze its efficacy and clinicopathological correlation. Multiple online databases and algorithms were used to analyze the correlation between MFAP2 and the tumor immune microenvironment. Immunophenotyping score (IPS) combined with immunotherapy patient cohort was used to analyze the value of MFAP2 in predicting the responsiveness of immunotherapy. Differential expression of MFAP2 in gastric cancer and adjacent tissues was verified with multiple datasets. Results: The blue module showed the highest correlation with survival outcomes of GC patients (R=0.17, P<0.001). Further intersections were taken with prognosis-related genes, and a total of 20 key genes were screened. High expression of the key gene MFAP2 suggested poor prognosis and pathological progression of GC (HR>1, P<0.05). MFAP2 was closely associated with cancer-associated fibroblasts, and GC patients with high expression of MFAP2 were more insensitive to immunotherapy. The high expression of MFAP2 mRNA in GC was verified by multiple datasets (P<0.05 or P<0.01). Conclusion: High expression of MFAP2 is a predictive factor for poor prognosis and response to immunotherapy in GC patients. MFAP2 is expected to serve as a novel therapeutic target and prognostic indicator for gastric cancer. [ABSTRACT FROM AUTHOR]

Leptomeningeal metastasis (LM) is a lethal complication of malignant tumors, with an incidence rate of 3%-5% among patients with non-small cell lung cancer (NSCLC). LM poses significant challenges in diagnosis, has poor prognosis, limited treatment options, and lacks standardized criteria for evaluating therapeutic efficacy, making it a dif- ficult aspect of NSCLC management. Circulating tumor DNA (ctDNA), shed from tumor cells and carrying cancer-related information, holds significant value in precision oncology. Cerebrospinal fluid (CSF), present in the subarachnoid space of the brain, the spinal cord, and the central canal, and in direct contact with meningeal tissues, serves as the fluid medium that best reflects the genetic characteristics of LM. In recent years, CSF ctDNA has become a focal point due to its multi-omics features, playing a crucial role in the management of central nervous system (CNS) metastatic tumors. Its applications span the entire continuum of care, including aiding in diagnosis, assessing treatment response, predicting prognosis, and analyzing resistance mechanisms. This article provides a concise overview of CSF ctDNA detection techniques and their clinical applications in patients with NSCLC-LM. [ABSTRACT FROM AUTHOR]

The advent of immune checkpoint inhibitors (ICIs) has greatly improved the prognosis of advanced lung cancer patients, but can lead to pseudoprogression (PsP), which complicates clinical evaluation and management. PsP is manifested as temporary enlargement of the tumour or the appearance of new lesions, etc., and improvement in imaging occurs with continued treatment, mostly without worsening of clinical symptoms. Currently, there are still difficulties in the early diagnosis of PsP, and its occurrence mechanism is not yet clear, lacking good predictive factors and related biomarkers. This article reviews the current research status of PsP of ICIs in non-small cell lung cancer in order to provide helpful clinical strategies for oncologists using these drugs. [ABSTRACT FROM AUTHOR]

With the popularization of chest computed tomography (CT) lung cancer screening, the detection rate of peripheral pulmonary nodules is increasing day by day. Some patients could make clear diagnoses and receive early treatment by obtaining biopsy specimens. Transbronchial lung biopsy (TBLB) is one of the non-surgical biopsy methods for peripheral pulmonary nodules, which has less trauma and lower incidence of complications compared to percutaneous thoracic needle biopsy (PTNB). However, the diagnostic rate of TBLB is about 70%, which is still inferior to that of PTNB, which is about 90%. Since 2018, robot assisted bronchoscopy systems have been applied in clinical practice. This article reviews their application in further improving the diagnostic rate of peripheral pulmonary nodules by TBLB. [ABSTRACT FROM AUTHOR]

Pancreatic cancer is a relatively common tumor of the digestive system， with difficulties in early-stage diagnosis and an extremely high degree of malignancy. Molecular diagnostic technology based on tumor biomarkers， combined with the existing gold standard in clinical practice， is of great clinical significance to achieve early accurate identification， timely treatment and intervention， and reduction in mortality. Previous studies have shown that miRNAs show high specificity in terms of types and expression levels in different pathological stages of pancreatic cancer and can thus be used in monitoring the development and progression of pancreatic cancer. Since a single miRNA has a limited diagnostic potential， the combination of different miRNAs may effectively improve the diagnostic efficiency of early-stage pancreas carcinogenesis. Based on related research advances in recent years， this consensus document aims to fill the gap in molecular diagnostic technology in the guidelines for the clinical diagnosis and treatment of pancreatic cancer and provide expert guidance and recommendations. [ABSTRACT FROM AUTHOR]

Background and objective Low-dose spiral computed tomography (LDCT) has been recommended for lung cancer screening in high-risk populations. However, evidence from Chinese populations was limited due to the different criteria for high-risk populations and the short-term follow-up period. This study aimed to evaluate the effectiveness in Chinese adults based on the Lung Cancer Screening Program in Minhang District of Shanghai initiated in 2013. Methods A total of 26,124 subjects aged 40 years or above were enrolled in the Lung Cancer Screening Program during the period of 2013 and 2017. Results of LDCT examination, and screen-detected cancer cases in all participants were obtained from the Reporting System of the Lung Cancer Screening Program. The newly-diagnosed cases and their vital status up to December 31, 2020 were identified through a record linkage with the Shanghai Cancer Registry and the Shanghai Vital Statistics. Standardized incidence ratio (SIR) and 95%CI were calculated using the local population at ages of 40 or above as the reference. Proportions of early-stage cancer (stage 0-I), pathological types, and 5-year observed survival rates of lung cancer cases were estimated and compared between the cases derived from the screened and non-screened populations. Cox regression models were applied to evaluate the hazard ratio (HR) and 95%CI of LDCT screening with all-cause death of the lung cancer cases. Results The crude and age-standardized incidence of lung cancer in screened population were 373.3 (95%CI: 343.1-406.1) and 70.3 per 100,000 person-years, respectively, with an SIR of 1.8 (95%CI: 1.6-1.9), which was observed to decrease with following-up time. The early-stage cancer accounted for 49.4% of all lung cancer cases derived from the screened population, significantly higher than 38.4% in cases from the non-screened population during the same period (P<0.05). The proportion of lung adenocarcinoma (40.7% vs 35.9%) and 5-year survival rate (53.7% vs 41.5%) were also significantly higher in the cases from the screened population (all P<0.05). LDCT screening was associated with 30% (HR=0.7, 95%CI: 0.6-0.8) reduced all-cause deaths of the cases. Conclusion The participants of the screening program are at high-risk of lung cancer. LDCT favors the early-detection of lung cancer and improves 5-year survival of the screened cases, indicating a great potential of LDCT in reducing the disease burden of lung cancer in Chinese populations. [ABSTRACT FROM AUTHOR]

Primary liver cancer (PLC) is one of the common malignant tumors and the main causes of tumor death in China. Although the diagnosis and treatment technology of PLC in China has made great progress in recent years, its morbidity and mortality have been decreasing year by year, but the low early diagnosis rate and 5-year survival rate of PLC are major public health problems that need to be solved urgently in the field of chronic disease prevention and control. Effective implementation of early screening, detection, diagnosis and treatment of PLC is an important measure to improve the rates of radical treatment and survival. The combination of serum alpha-fetoprotein (AFP) and liver ultrasound is a routine method for screening hepatocellular carcinoma (HCC) in patients with chronic liver disease; the combination of AFP and AFP-L3 and/or abnormal prothrombin can improve the early diagnosis rate of early-stage HCC; the early diagnosis rate of small hepatocellular carcinoma can be improved by Gd-EOB-DTPA-enhanced magnetic resonance imaging or its combination with computerized tomography. With the continuous promotion of hierarchical medical system and improvement of primary medical resources allocation and health service capacity in China, primary care institutions have become an important force for early screening of many cancers. Based on this context, this paper mainly discusses the development opportunities, risk challenges and future thinking of surveillance for liver cancer in primary care institutions in China, in order to provide new ideas and direction guidance for it in the future.

Objective To analyze the spatiotemporal distribution of patients with breast cancer detected in screening in Zibo, China, and to provide a scientific basis for prevention and treatment of the disease. Methods The breast cancer data were pooled from women aged 35-64 years from the rural areas in Zibo who were screened from 2019 to 2021. SPSS 19.0 and Microsoft Office were used for data processing, and ArcGIS 10.2 and SaTScan were used for trend analysis, spatial correlation analysis, and spatiotemporal scanning statistical analysis. Results From 2019 to 2021, 307 patients with breast cancer were detected; the detection rates in 2019, 2020, and 2021 were 64.70/100 000, 73.87/100 000, and 71.68/100 000, respectively, with an average 3-year detection rate of 70.62/100 000; there was a significant difference in the 3-year detection rate (χ2=11.889,P

Endometrial cancer is one of the three major gynecological cancers, and the proportion of endometrial cancer among women of childbearing age is increasing yearly. How to achieve effective, safe and economical prevention and control of endometrial cancer through early diagnosis and screening has become a major topic. At present, there are still huge challenges in the early diagnosis and screening of endometrial cancer, including inadequate methods and programs, uncertain screening objects, and lack of efficient and minimally or non-invasive methods. In recent years, the molecular and imaging protocols are gradually alleviating these difficulties, which are expected to become efficient and safe screening programs for endometrial cancer. This article is aimed to review the current status of endometrial cancer screening and the research progress of emerging molecular and imaging regimens of early screening and diagnosis of endometrial cancer, and explore the implementation of future screening strategies. [ABSTRACT FROM AUTHOR]

As the utilization of computed tomography in lung cancer screening becomes more prevalent in the post-pandemic era, the incidence of multiple primary lung cancer (MPLC) has surged in various countries and regions. Despite the continued application of advanced histologic and sequencing technologies in this research field, the differentiation between MPLC and intrapulmonary metastasis (IM) remains challenging. In recent years, the specific mechanisms of genetic and environmental factors in MPLC have gradually come to light. Lobectomy still predominates in the treatment of MPLC, but the observation that tumor-specific sublobar resection has not detrimentally impacted survival appears to be a viable option. With the evolution of paradigms, the amalgamated treatment, primarily surgical, is an emerging trend. Among these, stereotactic ablative radiotherapy (SABR) and lung ablation techniques have emerged as efficacious treatments for early unresectable tumors and control of residual lesions. Furthermore, targeted therapies for driver-positive mutations and immunotherapy have demonstrated promising outcomes in the postoperative adjuvant phase. In this manuscript, we intend to provide an overview of the management of MPLC based on the latest discoveries. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To summarize the best evidence for lung cancer screening and follow-up management of pulmonary nodules, and to provide reference for clinical practice. Methods Extensive literature search on lung cancer screening and follow-up management of pulmonary nodules was conducted in CNKI, WANFANG, VIP, PubMed, EMbase and Web of Science. The information extraction, quality evaluation and summary of evidence were carried out, and the retrieval period was up to December 1, 2022. Results A total of 33 articles were included in this study, including 5 guidelines, 2 expert consensuses, 2 expert recommendations, 14 systematic reviews and 10 cohort studies. Finally, 6 recommendations on lung cancer screening were concluded, including screening process, recommended screening age, recommended high-risk groups, recommended screening means, recommended screening frequency, and smoking cessation intervention among smokers. And 2 recommendations on pulmonary nodule management were concluded. Conclusion This study summarizes evidence of lung cancer screening and pulmonary nodules management, which can provide reference for health care personnel to conduct early screening and follow-up management of lung cancer in high-risk groups. [ABSTRACT FROM AUTHOR]

Copyright of Journal of China Medical University is the property of Journal of China Medical University Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

BACKGROUND: The DutchBelgian Randomized Lung Cancer Screening Trial (NELSON) used a volume-based protocol and significantly reduced the prevalence of false-positive results (2.1%). AIM: To compare the performance of manual linear diameter and semi-automated volumetric nodule measurement in the pilot project Moscow Lung Cancer Screening ultra-low-dose computed tomography pilot study. MATERIALS AND METHODS: The study included individuals with a lung nodule of at least 4 mm on baseline-computed tomography of the Moscow lung cancer screening between February 2017 and February 2018, without verified lung cancer diagnosis until 2020. The radiation dose was selected individually and did not exceed 1 mSv. All scans were assessed by three blinded readers to measure the maximum and minimum transversal nodule diameter and extrapolated volume. As a reference value of size and volume, the average value from the results of expert measurements was obtained. A false-positive nodule was defined as a nodule 6 mm/100 mm3 and a false-negative nodule as a nodule 6 mm/100 mm3. RESULTS: Overall, 293 patients were included (166 men; mean age, 64.6 5.3years); 199 lung nodules were 6 mm/100 mm3 and 94 were 6 mm/100 mm3. Regarding volumetric measurements, 32 [10.9%; 4 false-positive, 28 false-negative], 29 [9.9%; 17 false-positive, 12 false-negative], and 30 [10.2%; 6 false-positive, 24 false-negative] nodule discrepancies were reported by readers 1, 2, and 3 respectively. For linear diameter measurement, 92 [65.5%; 107 false-positive, 85 false-negative], 146 [49.8%; 58 false-positive, 88 false-negative], and 102 [34.8%; 23 false-positive, 79 false-negative] nodule discrepancies were reported by readers 1, 2, and 3 respectively. CONCLUSIONS: The use of lung nodule volumetry strongly reduces the number of false-positive and false-negative nodules compared with nodule diameter measurements, in an ultra-low-dose computed tomography lung cancer screening program.

In the article "Volumetry versus linear diameter lung nodule measurement: an ultra-low-dose computed tomography lung cancer screening study" published in Digital Diagnostics journal Volume 4 Issue 1 in 2023 (doi: 10.17816/DD117481) contained an error in the paragraph with data of funding sources for the study. At the request of the authors team, the error was eliminated, the original version of the published article and the information on the journals site was replaced with the corrected one. Correct text of the changed: This paper was prepared by a group of authors as part of the research work (USIS No. 123031400009-1) in accordance with the Order issued by the Moscow Health Care Department No. 1196 dated December 21, 2022. The authors and the publisher apologize to readers for the published error and express their confidence that this mistake could not significantly affect the perception and interpretation of the results of the study described in the text of the article.

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background & Problems: Early detection tests are highly effective in helping adult women prevent the onset of cervical cancer. However, the cervical Pap smear screening rate in a health management center was only 54.3% in 2020. Purpose: This project was developed to improve the Pap smear screening rate for cervical cancer in a health management center. Resolution: The strategies developed included revising the health examination lists, developing an online appointment booking system, designing a patient decision aid, creating a standardized simulation moulage for education, and rechecking patient's National Health Insurance cards. Result: After implementation of these strategies, the Pap smear screening rate for cervical cancer rose from 54.3% to 81.2%. The screening rate at the health management center in 2022 reached 96.6%. Conclusion: Shared decision-making can elucidate the comprehensive options available to clients and support them in considering their options and achieving informed choices regarding Pap smear preferences. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In recent years, with the popularization of early screening, the incidence and mortality rate of cervical cancer in China have decreased. Cytological examination and high -risk human papilloma virus (HPV) test are common screening methods for cervical cancer at present, but they both have their limitations. Cytological examination may lead to missed diagnosis, while high-risk HPV test may lead to over-diagnosis and over-treatment. Therefore, it is necessary to explore a new screening or triage method for cervical cancer. DNA methylation is a common epigenetic modality. With the development of DNA methylation detection technology, DNA methylation has played an increasingly important role in the field of oncology diagnosis and treatment. In recent years, a large amount of DNA methylation genes has been found as markers of cervical cancer, which have a promising application in cervical cancer screening and triage, and have the advantages of prognosis prediction and convenient sampling. DNA methylation is beneficial for the early diagnosis and treatment of cervical cancer. This article reviews the research progress of DNA methylation in cervical cancer and precancerous lesions. [ABSTRACT FROM AUTHOR]

For the high-risk population, early screening and diagnosis are important measures to achieve good control of liver cancer and reduce the burden of liver cancer, and determining the high-risk population of liver cancer and formulating appropriate liver cancer screening strategies are the key to realizing the early screening and diagnosis of liver cancer. The risk assessment model for liver cancer is an important method for rapid and convenient identification of the high-risk population of liver cancer. Based on the risk stratification of liver cancer, the methods such as imaging technology, serological markers, liquid biopsy, metabolomics, and glycomics can be used for accurate early screening and diagnosis of liver cancer, so as to achieve the goal of early treatment. [ABSTRACT FROM AUTHOR]

Immunotherapy based on immune checkpoint inhibitor (ICI) has become the main treatment strategy for advanced non-small cell lung cancer (NSCLC). By releasing immune checkpoint mediated immunosuppression, ICI restores the body's immune balance, improves the anti-tumor response rate, and significantly improves the prognosis of patients with advanced NSCLC. However, many problems remain unsolved in ICI treatment for advanced NSCLC. The present article will focus on the full-course management of ICI immunotherapy in advanced NSCLC patients, including prediction of immunotherapy efficacy, special patients screening before the initiation of ICI therapy, choice of the ICI drugs, development of new generation ICI drugs, restart of ICI immunotherapy after immune-related adverse event, ICI resistance, and the management of immune-related adverse events, in order to provide guidance for immunotherapy for advanced NSCLC patients. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To investigate the value of diffusion kurtosis imaging (DKI) histogram combined with Ephrin type-A receptor 2 (EphA2) in the evaluation of glioma grading. Methods A total of 183 patients with diffuse glioma [including 63 cases of low-grade glioma (LGG) and 120 cases of high-grade glioma (HGG)] who underwent neurosurgical resection and were confirmed by pathology at General Hospital of Eastern Theater Command from December 2015 to December 2019 were enrolled. All patients underwent conventional MRI and DKI examination [including fractional anisotropy (FA), mean diffusivity (MD), kurtosis fractional anisotropy (KFA), mean kurtosis (MK), mean kurtosis tensor (MKT)], and DKI histogram parameters (including mean, variance, median, 25% quantile, 75% quantile, skewness, kurtosis) were obtained. Immunohistochemical staining of EphA2 was performed. Univariate and multivariate Logistic regression analysis were used to screen the predictive factors of glioma grading, and based on these factors, the DKI histogram and the DKI histogram combined with EphA2 grading diagnostic prediction model were constructed, and the receiver operating characteristic curve (ROC) was drawn to evaluate its diagnostic efficiency. Spearman rank correlation analysis was used to explore the correlation between the DKI histogram parameters and the EphA2 grading. Results For HGG, the variance (t = - 2.050, P = 0.042) and 75% quantile (t = - 2.130, P = 0.035) of FA value, the variance (t = - 6.052, P = 0.000) and skewness (Z = - 3.326, P = 0.001) of MD value, the mean (t = - 3.094, P = 0.002), variance (t = - 2.228, P = 0.027), median (Z = - 3.444, P = 0.001), 25% quantile (t = - 3.022, P = 0.003) and 75% quantile (t = - 3.438, P = 0.001) of MK value, the mean (t = - 3.096, P = 0.002), variance (t = - 2.140, P = 0.028), median (t = - 3.701, P = 0.000), 25% quantile (t = - 3.033, P = 0.003) and 75% quantile (t = - 3.441, P = 0.000) of MKT value were higher than those of LGG. The FA value (Z = 4.489, P = 0.000), MK value (Z = 4.528, P = 0.000) and MKT value (Z = 4.528, P = 0.000) were significantly lower than those of LGG. Logistic regression analysis showed the skewness of FA value (OR = 0.484, 95%CI: 0.278-0.842; P = 0.010), variance of MD value (OR = 2.821, 95%CI: 1.231-6.466; P = 0.014) and 75% quantile of MKT value (OR = 2.581, 95%CI: 1.148-5.806; P = 0.022) were the predictive factors for glioma grading. The ROC curve showed the area under the curve (AUC) of DKI histogram parameters combined with EphA2 grading was 0.90 ± 0.02 (95%CI: 0.676-0.922, P = 0.000), which was better than DKI histogram (0.86 ± 0.02; 95%CI: 0.809-0.916, P = 0.000; Z = 1.114, P = 0.041). Spearman rank correlation analysis showed only MD kurtosis was negatively correlated with EphA2 grading (rs = - 0.267, P = 0.002). Conclusions The prediction model of DKI histogram combined with EphA2 grading can effectively improve the efficiency of grading diagnosis of glioma. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Lung cancer ranked the highest incidence rate and mortality among people over 60 years old in China. With the increasing social population and incidence of lung cancer, the treatment of elderly lung cancer patients has become a major concern. Due to the improvement of surgical techniques and the application of enhanced recovery after surgery in thoracic surgery, more elderly patients could tolerate surgical treatment. At the same time, with the improvement of health awareness and the popularization of early diagnosis and screening, more lung cancer can be detected at the early stage. However, considering the organ dysfunction, various complications, physical weakness and other factors of elderly patients, it is important to provide individualized surgical treatment for the elderly. Therefore, based on the latest research progress worldwide, the experts in relevant fields have developed this consensus which contributes to guide the preoperative evaluation, surgical strategy, intraoperative anesthesia management, and postoperative management for elderly patients of lung cancer. [ABSTRACT FROM AUTHOR]

Lung cancer is the leading cause of cancer-related death in China. The effectiveness of low-dose computed tomography (LDCT) screening has been further validated in recent years, and significant progress has been made in research on Identifying high-risk individuals, personalizing screening interval, and management of screen-detected findings. The aim of this study is to revise China national lung cancer screening guideline with LDCT (20 8 version). The China Lung Cancer Early Detection and Treatment Expert Group (CLCEDTEG) designated by the China's National Health Commission, and China Lung Oncolgy Group experts, jointly participated in the revision of Chinese lung cancer screening guideline (2023 version). Tis revision is based on the recent advances in LDCT lung cancer screening at home and abroad, and the epidemiology of lung cancer in China. The following aspects of the guideline were revised: ( ) lung cancer risk factors besides smoking were considered for the identification of high risk population; (2) LDCT scan parameters were further classified; (3) longer screening interval is recommended for individuals who had negative LDCT screening results for two consecutive rounds; (4) the follow-up interval for positive nodules was extended from 3 months to 6 months; (5) the role of multi-disciplinary treatment (MDT) in the management of positive nodules, diagnosis and treatment of lung cancer were emphasized. Tis revision clarifies the screening, intervention and treatment pathways, making the LDCT screening guideline more appropriate for China. Future researches based on emerging technologies, including biomarkers and artificial intelligence, are needed to optimize LDCT screening in China in the future. [ABSTRACT FROM AUTHOR]

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To summarize the characteristics of delayed facial paralysis (DFP) after retrosigmoid approach surgery for vestibular schwannoma and screen its related influencing factors. Methods A total of 171 patients with vestibular schwannoma treated in The First Affiliated Hospital of Zhengzhou University from January 2019 to May 2021 were included in the study. All patients underwent retrosigmoid approach surgery under neuroelectrophysiological monitoring. Before and after the surgery, facial paralysis was classified according to House - Brackmann (H - B) grade of facial nerve function. Univariate and multivariate forward Logistic regression analysis was used to screen related risk factors of DFP after vestibular schwannoma surgery. Results Patients were divided into DFP group (n = 19) and non- DFP (NDFP) group (n = 152) according to whether there was DFP after surgery. The tumor diameter in DFP group was smaller than that in NDFP group (t = 6.623, P = 0.001), the proportion of small tumors (χ² = 18.585, P = 0.000) and the proportion of slight adhesion between tumor and facial nerve (χ² = 21.442, P = 0.000) were higher than those in NDFP group. Logistic regression analysis showed small tumor (OR = 15.797, 95%CI: 3.324-75.081; P = 0.001) and slight adhesion between tumor and facial nerve (OR = 11.690, 95%CI: 3.413-40.042; P = 0.000) were risk factors for DFP after vestibular schwannoma surgery. Following up to one year after surgery, the recovery rate of facial nerve function (H-B grade I-II) in DFP group was 17/19. Conclusions The patients with small tumor volume and slight adhesion between tumor and facial nerve are prone to DFP, and the prognosis of facial nerve function in such patients is good. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Background and objective At present, more and more studies predict invasive adenocarcinoma (IAC) through three-dimensional features of pulmonary nodules, but few studies have confirmed that three-dimensional features have more advantages in diagnosing IAC than traditional two-dimensional features of pulmonary nodules. This study analyzed the differences of chest computed tomography (CT) features between IAC and minimally invasive adenocarcinoma (MIA) from three-dimensional and two-dimensional levels, and compared the ability of diagnosing IAC. The non-invasive adenocarcinoma group includes precursor glandular lesions (PGL) and minimally invasive adenocarcinoma (MIA). Methods The clinical data of 1,045 patients with ground glass opacity (GGO) from January to December 2019 were collected. Then the correlation between preoperative CT image characteristics and pathological results were analyzed retrospectively. The independent influencing factors for the identification of IAC were screened out according to two-dimensional and three-dimensional classification by multivariate Logistic regression and the cut-off point for the identification of IAC was found out through the receiver operating characteristic (ROC) curve. At last, the ability of diagnosing IAC was evaluated by Yoden index. Results The diameter of nodule, the diameter of solid component, the diameter of mediastinal window nodule in two-dimensional factors, and the volume of nodule, the volume of solid part and the average CT value in three-dimensional factors were independent risk factors for the diagnosis of IAC. These factors were arranged by Yoden index: solid partial volume (0.601)>nodule volume (0.536)>solid component diameter (0.525)>nodule diameter (0.518)>mediastinal window nodule diameter (0.488)>proportion of solid component volume (0.471)>1-tumor disappearance ratio (TDR) (0.468)>consolidation tumor ratio (CTR) (0.394)>average CT value (0.380). Conclusion The CT features of three-dimensional are better than two-dimensional in the diagnosis of IAC, and the size of solid components is better than the overall size of nodules. [ABSTRACT FROM AUTHOR]

For most cancers, clear intervention targets for primary prevention are lacking, due to unidentified high-risk causal factors. Consequently, the focus of cancer prevention and control in China has shifted towards early screening and treatment within the general population. This review outlines the significant challenges in research and practice of cancer prevention and control in China, including: ①inadequate understanding of the natural history of cancer; ② limited high-level evidence supporting cancer screening effectiveness and value; ③compromised efficiency and accuracy in current screening modality; and ④ insufficient universality and sustainability of the current screening practices, taking esophageal cancer as an example. To address these challenges, we propose potential coping strategies: ① establishing tailored technologies and pathways for cancer prevention and control based on population-based and clinical epidemiological studies using high-quality designs; ②breaking conventional constraints to establish a novel, efficient, and precision cancer screening strategy and modality that aligned with the frontline needs of cancer prevention and control; and ③establishing enhanced communication platforms among government policymaking departments, scientific research teams, and industrial institutions to foster collaboration and translation in the field of cancer prevention and control. Ultimately, through the collaboration of multiple disciplines and departments, we will jointly achieve the long-term goal of cancer prevention and treatment.

Copyright of Chinese Journal of Lung Cancer is the property of Chinese Journal of Lung Cancer and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Computer Engineering & Applications is the property of Beijing Journal of Computer Engineering & Applications Journal Co Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Angle Health Law Review is the property of Angle Publishing Co., Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)